BLACK DIAMOND THERAPEUTICS I (BDTX) Stock News

NASDAQ:BDTX - Nasdaq - US09203E1055 - Common Stock - Currency: USD

2.76 -0.03 (-1.08%)

After market: 2.76 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BDTX Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: The Motley Fool

Black Diamond (BDTX) Q2 Loss Narrows 47%

9 days ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

9 days ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Yahoo Finance - Mentions: RJF

Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise

a year ago - By: Benzinga

Looking Into Black Diamond Therapeutic's Recent Short Interest

a year ago - By: BusinessInsider

News Image

BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024

3 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

3 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

5 months ago - By: Benzinga - Mentions: CANF TNXP HQY INTS ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

5 months ago - By: Black Diamond Therapeutics, Inc

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

5 months ago - By: Black Diamond Therapeutics, Inc

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

5 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

5 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

9 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

10 months ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

a year ago - By: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

a year ago - By: Gyre Therapeutics, Inc. - Mentions: GYRE

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors